Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IC9-CAR19
- Development stage
- Phase 1
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IC9-CAR19 is an autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to target the CD19 antigen expressed on B-cell malignancies. The product incorporates a safety switch mechanism using the inducible caspase 9 (iC9) suicide gene, which can be pharmacologically activated by rimiducid (AP1903), allowing rapid elimination of the CAR-T cells in case of severe adverse events such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). This design aims to improve the safety profile of CD19-directed CAR-T therapies while maintaining antitumor efficacy. IC9-CAR19 is under clinical development for relapsed/refractory B-cell acute lymphoblastic leukemia and various B-cell lymphomas[1][2][3][4][5].
- Other names
- inducible caspase 9 CD19 CAR-TiC9-CAR19 cellsiC-9-CAR19 cellsiC 9-CAR19 cells
02
Targets
CD19 (B lymphocyte antigen CD19)iCasp9 (Inducible caspase-9)
Beyond the preview
Go deeper on IC9-CAR19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC9-CAR19.